Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.
In this week’s Homerun Slides, we talk about some of the Potential Adjunctive Treatments for Type 1 Diabetes including: Incretins, SGLT-2 Inhibitors, and Insulin Sensitizers….
Read More »Type 1 Diabetes Treatment Options, Part 5
Efficacy and Safety of an SGLT-2 Inhibitor with Insulin for Type 2s
Canagliflozin appears to offer significant benefits when used in conjunction with insulin therapy.
Read More »FDA Warns that Use of SGLT-2 Inhibitors Could Lead to Ketoacidosis in Some Patients
Proper patient education on hydration touted as method to reduce DKA… The FDA is continuing to investigate this safety issue and will determine whether changes are needed in the prescribing information for this class of drugs, called sodium-glucose cotransporter-2 (SGLT2) inhibitors. Patients should pay close attention for any signs of …
Read More »Combination of a DPP-4 and an SGLT-2 for Type 2’s
New treatment strategies have focused on both dipeptidyl peptidase (DPP)-4 inhibitors, and SGLT-2’s.
Read More »Canagliflozin Versus Glimepiride in T2DM Patients Taking Metformin
Canagliflozin shows good results when compared to glimepiride in type 2 diabetes patients who were taking metformin.
Read More »New Guideline Released on Pharmacological Management of Obesity
The Endocrine Society has released a clinical practice guideline on the pharmacological management of obesity that includes recommendations on strategies for prescribing weight loss drugs.
Read More »Dr. Timothy Garvey on Qsymia and Other New Therapies for Weight Loss
Steve Freed: Let’s start out with a little background about Qsymia and Belviq. What is the FDA allowing you to treat with the drugs? Dr. Timothy Garvey: In 2012, the FDA approved two new weight loss medications. In 2014, another medication was approved. That is three new medications. We hope …
Read More »Diabetes Mellitus 101 for Cardiologists, Part 12
In this week’s Homerun Slides, we continue our discussion of incretins and then examine the benefits of adding SGLT-2 inhibitors to patient medication regimens…. To download these slides in PowerPoint (.ppt) format, use this link: Diabetes Mellitus 101 for Cardiologists, Part 12 Other sets in this series: Diabetes Mellitus 101 for Cardiologists, Part …
Read More »Investigational SGLT-2 Inhibitor Works Even with Mild Renal Loss
Patients with type 2 diabetes and mild renal impairment experienced improved glycemic control when treated with ipragliflozin… According to lead author Atsunori Kashiwagi, MD, PhD, of Kusatsu General Hospital in Shiga, among patients with mild renal impairment, patients receiving ipragliflozin had a mean decrease in HbA1c of 0.56% at 6 …
Read More »FDA Approves Xigduo XR, a New Dapagliflozin-Metformin Combination
The once-daily oral tablet is the first in the U.S. to combine the SGLT-2 inhibitor dapagliflozin with the biguanide extended-release (XR) metformin hydrochloride.. The US Food and Drug Administration (FDA) has approved a once-daily combination of dapagliflozin and metformin hydrochloride extended-release (Xigduo XR, AstraZeneca) for the treatment of adults with …
Read More »